Evidence map›Paper›PMID 32127819›Full record

ArticleAfrican health sciences2019

Review of immunohistochemical typing of endometrial carcinoma at the Lagos University Teaching Hospital.

Olayemi Olubunmi Dawodu, Kehinde Sharafadeen Okunade, Adetola Daramola, Adekunbiola Aina Fehintola Banjo

Abstract read
In one paragraph

Article in African health sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Editorial.African health sciences · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Olayemi Olubunmi DawoduDepartment of Anatomic and Molecular Pathology, College of Medicine, University of Lagos.
Kehinde Sharafadeen OkunadeDepartment of Obstetrics & Gynaecology, College of Medicine, University of Lagos.
Adetola DaramolaDepartment of Anatomic and Molecular Pathology, College of Medicine, University of Lagos.
Adekunbiola Aina Fehintola BanjoDepartment of Anatomic and Molecular Pathology, College of Medicine, University of Lagos.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
FIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

backgroundCategorization of endometrial carcinomas as type I and II provides useful insights into their different risk factors, pathogenesis and biologic behaviours.

aimTo determine the immunohistochemical classifications of endometrial carcinomas in Nigerian women.

designA retrospective review of histopathologic slides of cases of endometrial carcinomas seen at the Lagos University Teaching Hospital (LUTH) over a 5-year period. The slides were reviewed, and the diagnoses made according to the WHO nomenclature. The classification of endometrial carcinomas into Type I and II was made by immunohistochemistry using antibodies to ER, PR, p53 and Ki-67.

resultsEight cases of endometrial adenocarcinoma were reported accounting for 53.3% of all endometrial malignancies. Of these, only 1 case showed the classic type I immunophenotype while type II staining pattern was seen in 4 cases. The remaining 3 cases had equivocal immunophenotypes: one was p53+ but showed ER+, PR+ and high Ki-67 index; the second was p53-, ER+, PR+ but had a high Ki-67 expression; while the last was p53-, but ER-, PR- and had high Ki-67 expression.

conclusionEndometrial carcinomas in Nigerian women are more likely to be type II carcinomas. A reasonable proportion of the cases were equivocal thus requiring further categorization with molecular studies.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorEndometrial NeoplasmsFemaleHospitals, UniversityHumansImmunohistochemistryImmunophenotypingKi-67 AntigenMiddle AgedNigeriaReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorKi-67 AntigenReceptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53Endometrial carcinomasimmunohistochemistryLUTHNigerian

Identifiers

PMID32127819
PMCPMC7040300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.